We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

97 hedge funds and large institutions have $193M invested in Catalyst Pharmaceutical in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more call options, than puts

Call options by funds: $928K | Put options by funds: $458K

40% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 25

14% more capital invested

Capital invested by funds: $169M → $193M (+$23.8M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less funds holding

Funds holding: 99 → 97 (-2)

3.07% less ownership

Funds ownership: 52.82% → 49.75% (-3.1%)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

Holders
97
Holders Change
-2
Holders Change %
-2.02%
% of All Funds
2.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
35
Reduced
25
Closed
14
Calls
$928K
Puts
$458K
Net Calls
+$470K
Net Calls Change
+$256K

Top Buyers

1
O
OrbiMed
New York
+$3.45M
2
PAM
Panagora Asset Management
Massachusetts
+$1.05M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$820K
4
BlackRock
BlackRock
New York
+$602K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$580K

Top Sellers

1
BC
Broadfin Capital
New York
-$5.13M
2
Millennium Management
Millennium Management
New York
-$4.62M
3
BBA
Baker Bros. Advisors
New York
-$2.26M
4
CM
Crestline Management
Texas
-$1.52M
5
OAM
Oxford Asset Management
United Kingdom
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$959K -$501K -159,864 -39%
TCM
27
Tanaka Capital Management
New York
$948K – – –
RJFSA
28
Raymond James Financial Services Advisors
Florida
$895K – – –
Prudential Financial
29
Prudential Financial
New Jersey
$833K -$274K -87,467 -28%
TA
30
Teachers Advisors
New York
$825K +$73.1K +23,321 +12%
Charles Schwab
31
Charles Schwab
California
$788K – – –
GCP
32
GSA Capital Partners
United Kingdom
$767K -$557K -177,760 -47%
PVI
33
Pura Vida Investments
New York
$765K +$164K +52,489 +35%
AQR Capital Management
34
AQR Capital Management
Connecticut
$751K -$554K -176,800 -47%
SO
35
STRS Ohio
Ohio
$720K -$102K -32,500 -15%
AA
36
ALPS Advisors
Colorado
$686K +$102K +32,661 +22%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$632K +$6.13K +1,956 +1%
Renaissance Technologies
38
Renaissance Technologies
New York
$577K +$19.6K +6,256 +4%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$562K +$3.06K +976 +0.7%
Millennium Management
40
Millennium Management
New York
$507K -$4.62M -1,476,157 -92%
BFM
41
Boothbay Fund Management
New York
$379K +$50.1K +16,000 +19%
Lido Advisors
42
Lido Advisors
California
$378K +$39.8K +12,699 +15%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$319K -$19.5K -6,225 -7%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$288K – – –
CC
45
Caxton Corporation
New Jersey
$276K +$123K +39,166 +116%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$258K -$29.4K -9,398 -12%
AIG
47
American International Group
New York
$242K +$3.61K +1,153 +2%
Two Sigma Advisers
48
Two Sigma Advisers
New York
$220K -$89K -28,400 -33%
California Public Employees Retirement System
49
California Public Employees Retirement System
California
$214K +$48.1K +15,368 +37%
SAM
50
Silphium Asset Management
United Kingdom
$214K – – –
1
2
3 4 5

CPRX Hedge Fund Activity: Q3 2018 in Review

97 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2018, worth a combined $193M — up 14% from $169M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CPRX and 12 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 35 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $3.45M. The largest seller was Broadfin Capital, cutting an estimated $5.13M.

  • 97 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2018, down from 99 in Q2 2018.
  • Funds reported $193M of Catalyst Pharmaceutical stock for Q3 2018, up 14% quarter-over-quarter.
  • 12 funds opened new Catalyst Pharmaceutical positions in Q3 2018 and 14 closed out, a net change of -2 holders.
  • The largest Catalyst Pharmaceutical buyer in Q3 2018 was OrbiMed, an estimated $3.45M added.
  • The largest Catalyst Pharmaceutical seller in Q3 2018 was Broadfin Capital, an estimated $5.13M sold.

Based on aggregated 13F filings for Q3 2018.